Regeneron Pharmaceuticals, Inc. (REGN, Financial) has been upgraded by Cantor Fitzgerald from a Neutral rating to Overweight. This change comes as a new analyst assumes responsibility for covering the stock. The analyst has set a revised price target for Regeneron, bringing it to $695, down from the previous target of $800.
The upgrade reflects the analyst's favorable outlook on Regeneron's potential performance and opportunities within its sector. Despite the lowered price target, the Overweight rating signals increased confidence in the company's future growth.
